Fidson to produce generic influenza drug, strengthen health security

Fidson Healthcare Plc has been selected to manufacture a generic version of Roche's influenza drug, baloxavir marboxil. The company is one of eleven manufacturers across nine countries to sign sublicense agreements with the Medicines Patent Pool for the development and manufacture of generic versions of the drug.

According to Nairametrics, Fidson is among four manufacturers with a global presence and six regionally focused manufacturers. The sublicense agreements mark an important step in strengthening systems and partnerships needed before the next health emergency.

The generic version of baloxavir marboxil will be supplied to 129 countries, as reported by Punch. The announcement of the sublicensees was made as global leaders gathered at the United Nations General Assembly in New York to discuss pandemic prevention, preparedness and response.

Brief written by urgent.news from Punch, Punch Nigeria, Nairametrics — 3 reports on this story. Machine-written — may contain errors; check the original before relying on it.